Related Experiment Video

Updated: Jun 21, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with

Z J Wang1, Y J Zhou, Y Y Liu

  • 1Department of Cardiology, Anzhen Hospital, Capital Medical University, Chaoyang district, Beijing, 100029, China.

Heart (British Cardiac Society)
|July 14, 2009
PubMed

Insights

Obesity increases the risk of cardiovascular thrombotic events after drug-eluting stent implantation. Obese patients undergoing percutaneous coronary intervention (PCI) experienced higher rates of cardiac death and myocardial infarction.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Obesity Medicine

Background:

  • Conflicting data exists on the relationship between body mass index (BMI) and outcomes after percutaneous coronary interventions (PCI).
  • Previous research has not specifically investigated the impact of obesity on cardiovascular thrombotic events post-stent implantation.

Purpose of the Study:

  • To assess the influence of obesity on cardiovascular thrombotic events in patients receiving drug-eluting stents during PCI.
  • To determine if obesity is an independent predictor of thrombotic events after PCI.

Main Methods:

  • A cohort of 4972 patients undergoing PCI with drug-eluting stents between 2004 and 2006 was analyzed.
  • Patients were stratified into normal (BMI <24.9 kg/m²), overweight (BMI 25-29.9 kg/m²), and obese (BMI ≥30 kg/m²) groups.
  • Median follow-up was 26 months, with analysis of composite thrombotic events and stent thrombosis.

Main Results:

  • Obese patients (BMI ≥30 kg/m²) had significantly higher rates of composite cardiovascular thrombotic events (5.9%) compared to normal (3.2%) and overweight (3.8%) individuals.
  • The incidence of stent thrombosis increased with rising BMI (0.9% in normal, 1.0% in overweight, 1.9% in obese).
  • Obesity independently predicted 3-year composite thrombotic events (HR 1.86) and stent thrombosis (HR 2.17).

Conclusions:

  • Obesity is associated with an elevated risk of long-term cardiovascular thrombotic events following PCI with drug-eluting stents.
  • These findings highlight the importance of weight management in patients undergoing PCI to mitigate thrombotic risks.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...